Abstract
A controversial proposal to have drug companies' “patient compliance” programmes declared legal in France has failed.
Critics described the proposal as a backdoor attempt to introduce into France direct to consumer drug advertising, which is currently banned throughout Europe.
Critics described the proposal as a backdoor attempt to introduce into France direct to consumer drug advertising, which is currently banned throughout Europe.
Original language | English |
---|---|
Pages (from-to) | 279-279 |
Number of pages | 1 |
Journal | BMJ (Clinical research ed.) |
Volume | 334 |
Issue number | 7588 |
DOIs | |
Publication status | Published - 10 Feb 2007 |